Kylo-0603
KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM) . KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research[1].
Product Specifications
CAS Number
2661053-09-2
UNSPSC
12352005
Target
Interleukin Related; LDLR; Thyroid Hormone Receptor
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Infection; Metabolic Disease
Smiles
Molecular Formula
C81H134N8O28
Molecular Weight
1667.97
References & Citations
[1]Xueqin lu, et al. KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the treatment of MASH. bioRxiv 2025.02.09.637336
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Claudin 9 (CLDN9) (NM_020982) Human Recombinant Protein
Human Microtubule Associated Protein 4 (MAP4) ELISA Kit
Human Microtubule Associated Protein 4 (MAP4) ELISA Kit
